Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics

Abstract

Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases, including COVID-19. However, their optimization is hindered by mRNA instability and inefficient protein expression. Here, we describe design principles that overcome these barriers. We develop an RNA sequencing-based platform called PERSIST-seq to systematically delineate in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load. We further introduce a method called In-line-seq, applied to thousands of diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic degradation. Our findings show that highly structured “superfolder” mRNAs can be designed to improve both stability and expression with further enhancement through pseudouridine nucleoside modification. Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.

Cited by papers we hold 6

• Nucleic acid drugs: recent progress and future perspectives · 2024
  No notice
• Engineered tRNAs suppress nonsense mutations in cells and in vivo · 2023
  No notice
• ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer · 2023
  No notice
• Algorithm for optimized mRNA design improves stability and immunogenicity · 2023
  No notice
• mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
  No notice
• The genetic and biochemical determinants of mRNA degradation rates in mammals · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.